Immunotherapy combination extends survival in advanced endometrial cancer
An immunotherapy-based regimen combining durvalumab and the PARP inhibitor olaparib demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson Cancer Center.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Adventurous play linked to better physical and mental health in children
United Kingdom
-
Black patients and people with learning disability face longer breast cancer care delays
United Kingdom
-
Sarcopenia should be treated as a motor system disease
United Kingdom
-
Researchers discover how faulty matrix structure leads to cell death in newly formed bone
United Kingdom
-
Exploring how autism reduces sensitivity to feedback on decisions
United Kingdom
-
Chest 'digital twin' predicts light paths to help plan personalized pneumonia treatment
United Kingdom
-
If Philadelphia Eagles quarterback Jalen Hurts can get dangerous blood clots, so can you
United Kingdom
-
Detailed brain map reveals how the insula shapes bodily sensations and processes pain
United Kingdom